References
- Antibody biosimilars: fears or opportunities? http://antibodybiosimilars.fr/en/index.html
- Laboratoire d’Excellence MAbImprove http://mabimprove.univ-tours.fr/?lang=en
- EMA guidelines on Biosimilars . http//www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general content 000408.jsp
- Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310 - 2; http://dx.doi.org/10.1038/nbt.1839; PMID: 21478841
- Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ureña S, Lim M, Lee YA, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72:1605 - 12; http://dx.doi.org/10.1136/annrheumdis-2012-203091; PMID: 23687259
- Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, Kovalenko V, Prodanovic N, Abello-Banfi M, Gutierrez-Ureña S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72:1613 - 20; http://dx.doi.org/10.1136/annrheumdis-2012-203090; PMID: 23687260